InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Entry into Ketamine Implant Therapeutic Research Project
Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, has entered a research and development agreement to study and develop a dosage and time-release ketamine implant for the treatment of fibromyalgia. According to the announcement, the project will include analytical testing services as well as small batch preclinical proof of concept extrusion trials. The project is designed to…